Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Ted White will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. ET. The presentation will include insights into Verrica's dermatology therapeutics, especially their late-stage product candidates, VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has a global license agreement with Lytix Biopharma for developing LTX-315 for dermatologic oncology.

Positive

• Ted White will present at a major healthcare conference, increasing visibility.
• Verrica focuses on significant unmet needs in dermatology with late-stage candidates VP-102 and VP-103.

Negative

• None.

WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Participants may access a live webcast of the event through the following link:
https://event.on24.com/wcc/r/3173547/7EB680169FF01818435F231AA17B51A2.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com

FAQ

What will Ted White discuss at the RBC Capital Markets Global Healthcare Conference for VRCA?

Ted White will present a business overview and insights on Verrica's product pipeline, particularly VP-102 and VP-103.

When is the presentation by Verrica at the RBC Capital Markets Conference?

The presentation is scheduled for May 19, 2021, at 5:25 p.m. ET.

What is VP-102 and its significance for Verrica Pharmaceuticals?

VP-102 is a late-stage product candidate aimed at treating molluscum, common warts, and external genital warts, addressing major unmet medical needs.

What collaboration has Verrica Pharmaceuticals entered regarding dermatologic oncology?

Verrica has a worldwide license agreement with Lytix Biopharma to develop LTX-315 for dermatologic oncology conditions.